Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Up 14.62%
As of Thursday, August 06, Zevra Therapeutics, Inc.’s ZVRA share price has surged by 14.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Up 10.73%
As of Thursday, August 06, Zevra Therapeutics, Inc.’s ZVRA share price has surged by 10.73%, which has investors questioning if this is right time to sell.Omar Beirat
Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Down 23.60%
As of Friday, July 24, Zevra Therapeutics, Inc.’s ZVRA share price has dipped by 23.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Down 24.36%
As of Friday, July 24, Zevra Therapeutics, Inc.’s ZVRA share price has dipped by 24.36%, which has investors questioning if this is right time to buy.Tudor Pop
Why Zevra Therapeutics, Inc.’s (ZVRA) Stock Is Down 6.03%
As of Friday, July 10, Zevra Therapeutics, Inc.’s ZVRA share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $744.7 | $671.5 | 41% |
|
| Shares Out (Mil) | 61.3 | 43.5 | 52% |
|
| Institutional Ownership | 98.3% | 84.6% | 78% |
|
| Float (Mil) | 53.9 | 47.3 | 49% |
|
| Beta | 0.92 | 0.71 | 55% |
|
| Avg Daily Volume (000s) | 817 | 293 | 68% |
|
| Price Change (52-week) |
40.6% | 69.4% | 76% |
|
| Growth | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 51.6% | 6.7% | 96% |
|
| Net Income (5yr) | 53.4% | (1.4%) | 95% |
|
| EPS (5yr) | 19.3% | 15.0% | 67 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.3% | (15.0%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $0.178 | $1.140 | $1.050 | |
| Month Ago EPS | $0.193 | $1.250 | $1.100 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.223 | $1.190 | $2.227 | |
| Year/Year Chg | 27.1% | (15.6%) | 24.4% | |
| Financials | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $136 | $317 | 29% |
|
| Net Income (TTM) (Mil) | $58 | ($11) | 56% |
|
| EPS (TTM) | $0.996 | ($0.700) | 61% |
|
| Operating Cash Flow (TTM) (Mil) | $33 | ($6) | 44% |
|
| Net Cash Flow (TTM) (Mil) | $98 | $5 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 16% |
|
| Enterprise Value (Q1) (Mil) | $466 | $536 | 33% |
|
| Valuation | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.42 | 2.81 | 69% |
|
| P/E | 13.1 | 17.1 | 30% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.7 | 1.1 | 33% |
|
| Ratios | ZVRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 95.5% | 68.1% | 95% |
|
| Net Margin | 42.8% | (1.4%) | 95% |
|
| ROA | 20.8% | (24.1%) | 96% |
|
| ROE | 34.8% | (21.0%) | 89% |
|
| Liabilities to Assets | 28.1% | 32.3% | 20% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 9/3/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 7.2% |
| +/- S&P 500: | -0.3 |
